Verily


Verily Life Sciences, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. This restructuring process was completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

Researchers

As of July 2014, members of the research team include Andrew Conrad, founder of LabCorp's National Genetics Institute; Vik Bajaj, an expert in nuclear magnetic resonance; Marija Pavlovic, who studies the effect of radiation on DNA; Alberto Vitari, a cancer biologist; Brian Otis, who worked on Google Venture's glucose-sensing contact lens; and Mark DePristo, who worked on the Genome Analysis Toolkit at the Broad Institute. Dr. Thomas R. Insel announced on September 15, 2015 that he was resigning as the director of the National Institute of Mental Health to join this division.

Acquisitions and funding

On 9 September 2014, the division acquired Lift Labs, the makers of Liftware.
Verily Life Sciences in January 2019 raised $1 billion in funding. Andy Conrad remained CEO.
At the end of 2019, Verily sold its stake in robot-assisted surgery joint venture Verb Surgical to development partner Johnson & Johnson for an undisclosed sum.

Projects